Uveal melanoma (UM) is the most common primary intraocular cancer in adults, with up to 50% of patients developing fatal metastases. Current prognostic tests rely on tumor tissue obtained through invasive biopsy or enucleation, which limits their routine clinical use.

To address this challenge, researchers are developing the first aqueous humor (AH)-based molecular test for UM metastatic risk. Using Olink Explore, they profiled a broad range of proteins in microliter-volume AH samples, identifying an initial panel of candidate biomarkers. Follow-up analysis with the Olink Target 48 panel refined these findings, leading to a core biomarker set with strong potential for risk stratification research.

This minimally invasive, scalable approach could advance biomarker discovery in uveal melanoma and open new opportunities for oncology research.

What you’ll learn in this 30-minute session:

• How protein profiling of AH samples can reveal novel biomarkers for uveal melanoma risk stratification
• How the Olink PEA workflow, from Explore to Target 48, supports stepwise discovery-to-clinical translation in oncology research
• The potential of a liquid biopsy approach to deliver minimally invasive, scalable research in ocular oncology

Organised in collaboration with LuminoDX